LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

Search

ResMed Inc

Fechado

SetorSaúde

240.36 -2.68

Visão Geral

Variação de preço das ações

24h

Atual

Mín

236.49

Máximo

246.97

Indicadores-chave

By Trading Economics

Rendimento

44M

393M

Vendas

87M

1.4B

P/E

Médio do Setor

24.993

66.845

Rendimento de Dividendos

0.89

Margem de lucro

27.593

Funcionários

10,600

EBITDA

63M

566M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+21.66% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

0.89%

2.25%

Próximos Ganhos

22 de abr. de 2026

Próxima data de dividendos

19 de mar. de 2026

Próxima data de ex-dividendo

7 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-371M

37B

Abertura anterior

243.04

Fecho anterior

240.36

Sentimento de Notícias

By Acuity

17%

83%

15 / 351 Ranking em Healthcare

ResMed Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

10 de mar. de 2026, 20:38 UTC

Ganhos

Oracle Raises 2027 Sales Outlook Amid AI Demand, Restructuring

10 de mar. de 2026, 23:57 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

10 de mar. de 2026, 23:57 UTC

Conversa de Mercado

Risks Rising on Australian Bank Valuation Multiples -- Market Talk

10 de mar. de 2026, 23:47 UTC

Conversa de Mercado

Nikkei May Rise as Concerns About Energy Costs Ease -- Market Talk

10 de mar. de 2026, 23:37 UTC

Aquisições, Fusões, Aquisições de Empresas

Yangzijiang Shipbuilding to Acquire Poseidon Stake for US$825.7M

10 de mar. de 2026, 23:37 UTC

Aquisições, Fusões, Aquisições de Empresas

Yangzijiang Shipbuilding to Buy 10% Stake in Poseidon

10 de mar. de 2026, 23:37 UTC

Aquisições, Fusões, Aquisições de Empresas

Yangzijiang Shipbuilding to Fund Deal With Internal Cash Resources

10 de mar. de 2026, 23:37 UTC

Aquisições, Fusões, Aquisições de Empresas

Yangzijiang Shipbuilding to Buy Stake From Fairfax, Washington Family Affiliates

10 de mar. de 2026, 23:35 UTC

Conversa de Mercado
Notícias Principais

Gold Edges Higher as It Faces Opposing Forces -- Market Talk

10 de mar. de 2026, 23:06 UTC

Ganhos

Oracle Raises 2027 Sales View as AI Demand Outpaces Supply -- Update

10 de mar. de 2026, 22:51 UTC

Notícias Principais

Deleted Tweet From Energy Secretary Sends Oil Markets on Another Wild Ride -- Updated

10 de mar. de 2026, 21:39 UTC

Aquisições, Fusões, Aquisições de Empresas

Bill Ackman Has a Stroke of Genius. Buy His New Fund and Get Shares of His Pershing Square IPO. -- Barrons.com

10 de mar. de 2026, 21:21 UTC

Ganhos

Oracle Stock Jumps on Earnings Beat. Its Cloud Business Is Taking Over. -- Barrons.com

10 de mar. de 2026, 21:15 UTC

Ganhos

Franco-Nevada: 2026 Total GEOs Expected to Range From 510,000 to 570,000 Ounces

10 de mar. de 2026, 21:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Paramount Skydance's Stock Fades. The Warner Bros. Merger Will Take Years to Pay Off, BofA Says. -- Barrons.com

10 de mar. de 2026, 21:14 UTC

Ganhos

Franco-Nevada: Methodology Replaces Previous Variable GEO Conversion Ratios Based on Prevailing Market Prices

10 de mar. de 2026, 21:13 UTC

Ganhos

Franco-Nevada: Beginning in 2026, Company Will Be Adopt Fixed GEO Conversion Ratios Based on the Pricing Assumptions Outlined in 2026 Guidance

10 de mar. de 2026, 21:12 UTC

Ganhos

Franco-Nevada 4Q Rev $597.3M >FNV

10 de mar. de 2026, 21:12 UTC

Ganhos

Franco-Nevada 4Q EPS $1.90

10 de mar. de 2026, 20:57 UTC

Ganhos

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 de mar. de 2026, 20:50 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

10 de mar. de 2026, 20:44 UTC

Ganhos

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 de mar. de 2026, 20:34 UTC

Conversa de Mercado
Ganhos

Global Equities Roundup: Market Talk

10 de mar. de 2026, 20:34 UTC

Conversa de Mercado
Ganhos

Oracle Building More Software for Less Money After Restructuring -- Market Talk

10 de mar. de 2026, 20:23 UTC

Ganhos

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 de mar. de 2026, 20:16 UTC

Ganhos

NIO Stock Jumps After Earnings. How the EV Maker Delivered a Surprise Profit. -- Barrons.com

10 de mar. de 2026, 20:14 UTC

Ganhos

Oracle Has Not Yet Initiated At-The-Market Equity Portion of Financing Program >ORCL

10 de mar. de 2026, 20:14 UTC

Ganhos

Oracle Said In February It Intends to Raise Up to $50 B Dollars in Debt and Equity Financing >ORCL

10 de mar. de 2026, 20:13 UTC

Ganhos

Oracle Raised $30 B Through Combination of Investment Grade Bonds and Mandatory Convertible Preferred Stk Within Days of Feb Announcement >ORCL

10 de mar. de 2026, 20:12 UTC

Ganhos

Oracle Stock Jumps on Earnings Beat -- Barrons.com

Comparação entre Pares

Variação de preço

ResMed Inc Previsão

Preço-alvo

By TipRanks

21.66% parte superior

Previsão para 12 meses

Média 300.64 USD  21.66%

Máximo 345 USD

Mínimo 265 USD

Com base em 13 analistas de Wall Street que oferecem metas de preço de 12 meses para ResMed Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

13 ratings

8

Comprar

5

Manter

0

Vender

Sentimento

By Acuity

15 / 351 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre ResMed Inc

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
help-icon Live chat